Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2016

01-04-2016 | Melanoma (RJ Sullivan, Section Editor)

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Authors: Claire F. Friedman, Michael A. Postow

Published in: Current Oncology Reports | Issue 4/2016

Login to get access

Abstract

The immune system plays an essential role in the surveillance and eradication of neoplastic cells. This interaction is modulated via immunologic regulators (checkpoints). Antibodies that block the checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the programmed cell death protein 1 pathway (PD1/PD-L1) have demonstrated efficacy in a number of malignancies. However, response rates are variable, and administration of these antibodies can be associated with immune-related adverse events. Therefore, researchers are engaged in an effort to discover biomarkers that may predict response to these agents. This review focuses on potential blood and tumor-based biomarkers that have been assessed in patients treated with these checkpoint-blocking antibodies.
Literature
1.
Robert C et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.CrossRefPubMed
2.
Robert C et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.CrossRefPubMed
3.
Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.CrossRefPubMed
4.
Wolchok JD et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64.CrossRefPubMed
5.
Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.CrossRefPubMed
6.
Gettinger SN et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.CrossRefPubMed
7.
Motzer RJ et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.CrossRefPubMed
8.
Le DT et al. PD-1 blockade in tumors with mismatch repair deficiency. ASCO Meet Abstr. 2015;33(15_suppl):LBA100.
9.
Templeton AJ, Templeton AJ, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.CrossRefPubMed
10.
Zaragoza J, et al. Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol. 2015.
11.
Ferrucci PF et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015;112(12):1904–10.CrossRefPubMed
12.
Simeone E et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014;63(7):675–83.CrossRefPubMed
13.
Ku GY et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer. 2010;116(7):1767–75.CrossRefPubMedPubMedCentral
14.
Postow MA, et al. Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. ASCO Meeting Abstracts, 2013. 31(15_suppl):9052.
15.
16.
Callahan MK et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. ASCO Meet Abstr. 2013;31(15_suppl):3003.
17.
Gaba L et al. Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. ASCO Meet Abstr. 2015;33(15_suppl):9069.
18.
Kim DW et al. Predictive markers for programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis blockade therapy in patients with metastatic melanoma (MM). ASCO Meet Abstr. 2015;33(15_suppl):e20029.
19.
Valpione S et al. Personalised medicine: development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. Eur J Cancer. 2015;51(14):2086–94.CrossRefPubMed
20.
Gnjatic S et al. NY‐ESO‐1: review of an immunogenic tumor antigen. In: Advances in Cancer Research. Academic Press; 2006. p. 1–30.
21.
Yuan J et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008;105(51):20410–5.CrossRefPubMedPubMedCentral
22.
Yuan J et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011;108(40):16723–8.CrossRefPubMedPubMedCentral
23.
Goff SLMD et al. No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma. J Immunother. 2009;32(8):884–5.CrossRefPubMed
24.
Weide B et al. Functional T cells targeting NY-ESO-1 or Melan-a Are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012;30(15):1835–41.CrossRefPubMed
25.
Hutloff A et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397(6716):263–6.CrossRefPubMed
26.
Liakou CI et al. CTLA-4 blockade increases IFNγ-producing CD4 + ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008;105(39):14987–92.CrossRefPubMedPubMedCentral
27.
Carthon BC et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a Presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861–71.CrossRefPubMedPubMedCentral
28.
Ng Tang D et al. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2013;1(4):229–34.CrossRefPubMed
29.
Postow M et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. J Transl Med. 2014;12 Suppl 1:O8.CrossRefPubMedCentral
30.
31.
32.
Postow MA et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer. 2015;3:23.CrossRefPubMedPubMedCentral
33.
34.
35.
Filipazzi P et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25(18):2546–53.CrossRefPubMed
36.
Tarhini AA et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705.CrossRefPubMedPubMedCentral
37.
Meyer C et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–57.CrossRefPubMed
38.
Callahan M et al. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J ImmunoTher Cancer. 2013;1 Suppl 1:O6.CrossRefPubMedCentral
39.
40.
Grosso J et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). ASCO Meet Abstr. 2013;31(15_suppl):3016.
41.••
Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. This was the first paper to examine the role of PD-1/PD-L1 as a potential biomarker of response to PD-1 blockade.CrossRefPubMed
42.
Postow MA et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.CrossRefPubMed
43.
Wolchok JD et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.CrossRefPubMed
44.
Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015.
45.
Madore J et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28(3):245–53.CrossRefPubMed
46.••
Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. Tumeh and colleagues elegantly characterize the tumor immune microenvironment and relationship between tumor infiltrating lymphocytes and response to immunotherapy.CrossRefPubMedPubMedCentral
47.
Ji RR et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(7):1019–31.CrossRefPubMed
48.
Hamid O et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.CrossRefPubMedPubMedCentral
49.
Ribas A et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. ASCO Meet Abstr. 2015;33(15_suppl):3001.
50.
51.
van Rooij N et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439–42.CrossRefPubMed
52.••
Snyder A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99. This is a seminal paper which establishes the role of mutational load in predicting response to immunotherapy, as well as the potential homology between neoepitopes and viral and bacterial antigens.CrossRefPubMedPubMedCentral
53.
Rizvi NA et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.CrossRefPubMed
54.
Weber JS et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311–8.CrossRefPubMedPubMedCentral
55.
Antonia SJ et al. P2.11-035 Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients treated with non-small cell lung cancer (NSCLC) treated with nivoluamb (Anti-PD-1; BMS-936558; ONO-4538). J Thorac Oncol. 2013;8:S1–S1410.
56.
Daud AI. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome [abstract]. Proc. Ann. Meeting AACR, 2014: p. CT104.
57.
Gandhi L. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression [abstract]. Proc. Ann. Meeting AACR, 2014: p. CT105.
58.
Seiwert TY et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. ASCO Meet Abstr. 2014;32(15_suppl):6011.
59.
Ribas A et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO Meet Abstr. 2014;32(15_suppl):LBA9000.
60.
Hamid O et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). ASCO Meet Abstr. 2013;31(15_suppl):9010.
61.
Soria JC et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer. 2013;49:S97–S153.CrossRef
62.
Powles T et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.CrossRefPubMed
63.
Segal NH et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meet Abstr. 2014;32(15_suppl):3002.
64.
Rizvi NA et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2015;33(15_suppl):8032.
65.
Segal NH et al. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. ASCO Meet Abstr. 2015;33(15_suppl):3011.
Metadata
Title
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition
Authors
Claire F. Friedman
Michael A. Postow
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Oncology Reports / Issue 4/2016
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-016-0509-x

Other articles of this Issue 4/2016

Current Oncology Reports 4/2016 Go to the issue

Cardio-oncology (EH Yang, Section Editor)

Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future

Gynecologic Cancers (NS Reed, Section Editor)

What Is the Best Preoperative Imaging for Endometrial Cancer?

Gynecologic Cancers (NS Reed, Section Editor)

Brachytherapy in Gynecologic Cancers: Why Is It Underused?

Gynecologic Cancers (NS Reed, Section Editor)

Lymphovascular Space Invasion as a Risk Factor in Early Endometrial Cancer

Gynecologic Cancers (NS Reed, Section Editor)

New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits